Activation of Soluble Guanylate Cyclase Reverses Experimental Pulmonary Hypertension and Vascular Remodeling
Author(s) -
Rio Dumitrascu,
Norbert Weißmann,
Hossein A. Ghofrani,
Eva Dony,
Knut Beuerlein,
Harald Schmidt,
JohannesPeter Stasch,
Mark Jean Gnoth,
Werner Seeger,
Friedrich Grimminger,
Ralph T. Schermuly
Publication year - 2006
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.105.581405
Subject(s) - pulmonary hypertension , medicine , right ventricular hypertrophy , hypoxia (environmental) , nitric oxide , lung , soluble guanylyl cyclase , endocrinology , muscle hypertrophy , pulmonary artery , vascular remodelling in the embryo , vascular resistance , nitric oxide synthase , hemodynamics , cardiology , guanylate cyclase , oxygen , chemistry , organic chemistry
Severe pulmonary hypertension is a disabling disease with high mortality, characterized by pulmonary vascular remodeling and right heart hypertrophy. Using wild-type and homozygous endothelial nitric oxide synthase (NOS3(-/-)) knockout mice with pulmonary hypertension induced by chronic hypoxia and rats with monocrotaline-induced pulmonary hypertension, we examined whether the soluble guanylate cyclase (sGC) stimulator Bay41-2272 or the sGC activator Bay58-2667 could reverse pulmonary vascular remodeling.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom